According to the DAMP-related signature, low-risk patients are candidates for ICI therapy because a higher TIDE score was associated with a greater likelihood of tumor immune escape and decreased benefit from anti-PD-1/CTLA4 therapy [25]. This evidence concerns the gene CTLA4 and neoplasm.